AMENDED & RESTATED SEVERANCE RIGHTS AGREEMENTSeverance Rights Agreement • March 14th, 2013 • Xenoport Inc • Pharmaceutical preparations • California
This Amended & Restated Severance Rights Agreement (the “Agreement”) is made and entered into by and between KENNETH C. CUNDY, PHD (the “Executive”) and XENOPORT, INC., a Delaware corporation (the “Company”), effective as of December 20, 2012 (the “Effective Date”). The Company appreciates the important contributions that the Executive has made as XenoPort Fellow since June 2012. The Company and the Executive now desire that the Executive continue in his current role in a more formal, non-transitional, capacity. Therefore, this Agreement replaces and supersedes all prior agreements on the subject matter of this Agreement, including, but not limited to, the Severance Rights Agreement between the Executive and the Company dated June 1, 2012 (the “Prior Agreement”).
CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, IS FILED WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. TERMINATION AND TRANSITION AGREEMENTTermination and Transition Agreement • March 14th, 2013 • Xenoport Inc • Pharmaceutical preparations • Delaware
THIS TERMINATION AND TRANSITION AGREEMENT (“Termination Agreement”) dated as of November 8, 2012 (“Termination Effective Date”), is entered into between XenoPort, Inc., a Delaware corporation having its principal place of business at 3410 Central Expressway, Santa Clara, CA 95051 (“XenoPort”), and Glaxo Group Limited, a company existing under the laws of England and Wales, having its registered office at Glaxo Wellcome House, Berkeley Avenue, Greenford, Middlesex, UB6 0NN, England (“GSK”).
STOCK PURCHASE AGREEMENTStock Purchase Agreement • March 14th, 2013 • Xenoport Inc • Pharmaceutical preparations • Delaware
This STOCK PURCHASE AGREEMENT (the “Agreement”), is made as of November 8, 2012, by and between XenoPort, Inc., a Delaware corporation (the “Company”), and Glaxo Group Limited, a company existing under the laws of England and Wales (the “Purchaser”).
LEASE AMENDMENT AND TERMINATION AGREEMENTLease Amendment and Termination Agreement • March 14th, 2013 • Xenoport Inc • Pharmaceutical preparations • California
This Lease Amendment and Termination Agreement (this “Amendment”) is dated for reference purposes as of February 12, 2013, by and between SI 34, LLC, a California limited liability company (“Landlord”) and XenoPort, Inc., a Delaware corporation (“Tenant”).
